Merck: Keytruda wins EU approval for head and neck cancer
(CercleFinance.com) - Merck said on Wednesday that its blockbuster cancer drug Keytruda has won approval from European health regulators to treat head and neck cancer.
The immunotherapy drug has been approved by the European Commission for use as a monotherapy, or in combination with chemotherapy, to treat patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma, the US drugmaker said.
Head and neck cancer describes a number of different tumors that develop in or around the throat, larynx, nose, sinuses and mouth. Most of them are squamous cell carcinomas.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The immunotherapy drug has been approved by the European Commission for use as a monotherapy, or in combination with chemotherapy, to treat patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma, the US drugmaker said.
Head and neck cancer describes a number of different tumors that develop in or around the throat, larynx, nose, sinuses and mouth. Most of them are squamous cell carcinomas.
Copyright (c) 2019 CercleFinance.com. All rights reserved.